Protein therapies are front and center of medical treatments with over 80 drugs approved worldwide and over 170 in active clinical development. Downstream processing of protein products accounts for 50 – 80% of the total cost of production, with a large portion of expenses going towards the protein extraction process. With the protein production industry currently valued at $284.5 billion, there is a demand for a cheaper, more sustainable, and energy-efficient alternative. Using genetic engineering, Cellyse proposes a novel lytic technology which offers researchers and fermentation companies a way to extract recombinant proteins with only water. Our technology can expand biologics production through its ease of use and nontrivial cost reductions—paving the way for more affordable and equitable healthcare globally. Beyond optimizing extraction, our genetic construct also allows for valuable nutrients otherwise lost in purification to be recycled in the fermentation process, eliminating waste from over 255 million liters of cell culture media annually.